NeuroBo Pharmaceuticals (NASDAQ: NRBO) stock soared about 70% on Thursday after the FDA approved its Investigational New Drug (IND) application for DA-1726, a promising treatment for obesity.
NeuroBo (NRBO) has just received the green light from the U.S. Food and Drug Administration (FDA) for its new obesity treatment, DA-1726. This means they can now move forward with testing it on people.
DA-1726 is a fresh approach to tackling obesity. It’s a form of medicine that could help people lose weight by changing their bodies to deal with food. The company plans to start testing it on humans in the first half of this year.
DA-1726 works uniquely. It’s a dual oxyntomodulin (OXM) analog agonist that targets two crucial receptors in the body: the glucagon-like peptide-1 receptor (GLP1R) and the glucagon receptor (GCGR). According to early studies, this double action could lead to weight loss by making people eat less and burn more energy.
In tests on animals, DA-1726 showed effective results. It led to more weight loss than another well-known drug called liraglutide (Wegovy™) and similar weight loss to tripeptide (Mounjaro™), even though the animals ate more food.
Phase 1 Trial Overview
The next phase involves a Phase 1 clinical trial, a significant human testing stage with approximately 45 participants in one segment and around 36 in another. The study aims to evaluate the drug’s safety, its impact on the body, and potential effects on factors such as heart health and metabolism.
The trial will keep a close eye on safety, watching out for any problems that might come up. They’ll also focus on how the drug moves through the body and its impact on various health measures like body weight and cholesterol levels.
NeuroBo’s CEO, Hyung Heon Kim, is optimistic about DA-1726, citing its dual receptor activation and potential in the obesity market. The drug will be administered soon, with results expected by mid-2025.
NeuroBo (NASDAQ: NRBO) Stock Movement
NRBO stock soared 67.28% on Thursday. The traders had exchanged hands with 67,155,030 (67.15 million) shares compared to the average daily trading volume of 34.39K.
Edward Cooke is a financial analyst, freelance writer, and editor. He has six years of experience in financial journalism. He has an in-depth understanding of equities markets, tracking major indices and providing real-time analysis on stock price movements, corporate earnings, and market sentiment.
